Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2
AUTOR(ES)
Manning, Brendan D.
FONTE
Cold Spring Harbor Laboratory Press
RESUMO
The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes. Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes. Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt. However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity. This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1182339Documentos Relacionados
- A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles
- TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth
- The Methylation of the TSC2 Promoter Underlies the Abnormal Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells
- Tsc2 is not a critical target of Akt during normal Drosophila development
- Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling